Valuation: Mangalam Drugs & Organics Limited

Market Cap 489M 5.15M 4.58M 4.24M 3.86M 7.28M 7.41M 50.94M 20.01M 255M 19.31M 18.9M 813M P/E 2025
17.5x
P/E 2026 -0.99x
Enterprise Value 1.61B 16.95M 15.08M 13.96M 12.72M 23.97M 24.4M 168M 65.87M 839M 63.59M 62.24M 2.68B EV / Sales 2025
0.66x
EV / Sales 2026 0.67x
Free-Float
62.31%
Yield 2025 *
-
Yield 2026 -
08-17 Mangalam Drugs and Organics Limited Discloses Default on Bank Loan Accounts with Bank of Baroda and Bank of Maharashtra CI
08-12 Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-17 Mangalam Drugs and Organics Ltd. Defaults on Loan Obligations to Bank of Baroda and Bank of Maharashtra CI
05-14 Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
04-17 Mangalam Drugs & Organics Limited Announces Resignation of Anuradha Pandey as Company Secretary & Compliance Officer, Effective March 29, 2026 CI
04-16 Mangalam Drugs and Organics Limited Defaults on Loan Obligations Exceeding 30 Days with INR 95.197 Million to Bank of Maharashtra and INR 60.608 Million to Bank of Baroda CI
03-26 Mangalam Drugs and Organics Limited Appoints Shweta Patel as Company Secretary & Compliance Officer, Effective April 1, 2026 CI
03-17 Mangalam Drugs and Organics Limited Reports Loan Defaults Exceeding 30 Days on Bank Borrowings CI
03-17 Mangalam Drugs and Organics Limited Defaults on Loan Obligations to Bank of Maharashtra and Bank of Baroda CI
03-17 Mangalam Drugs and Organics Limited Defaults on Bank Loan Obligations Exceeding 30 Days with INR 70.705 Million to Bank of Maharashtra and INR 44.677 Million to Bank of Baroda CI
03-17 Mangalam Drugs and Organics defaults on loan obligations to Bank of Baroda, Bank of Maharashtra RE
02-06 Mangalam Drugs and Organics names Jeevan M. Dalvi as CFO RE
02-06 Mangalam Drugs and Organics Limited Approves the Appointment of Jeevan Mukund Dalvi as Chief Financial Officer, Effective February 6, 2026 CI
1 day-2.37%
1 week-1.97%
Current month+0.59%
1 month-3.50%
3 months+12.13%
6 months+3.87%
Current year+11.92%
1 week 30.62
Extreme 30.62
33.32
1 month 28.05
Extreme 28.05
34.99
Current year 25.7
Extreme 25.7
54.51
1 year 22.7
Extreme 22.7
72.95
3 years 22.7
Extreme 22.7
144.65
5 years 22.7
Extreme 22.7
172.65
10 years 20.4
Extreme 20.4
225.9
Manager TitleAgeSince
Chief Executive Officer 73 29/09/2011
Director of Finance/CFO - 05/02/2026
Compliance Officer 27 31/03/2026
Director TitleAgeSince
Chairman 73 01/02/2010
Director/Board Member 75 04/02/2015
Director/Board Member 38 27/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
-2.37%-1.97%-55.28%-68.81% 5.15M
+0.43%+6.59%+53.41%+103.85% 1,120B
+0.90%-2.25%+33.02%+62.23% 616B
+0.71%+3.24%+25.81%+93.86% 504B
-0.13%+5.98%+32.91%+50.39% 367B
+0.52%+0.24%+73.92%+40.15% 360B
-0.95%+4.70%+19.51%+43.00% 288B
-1.98%+3.73%-0.86%+13.43% 258B
-0.35%+4.25%+46.21%+50.76% 234B
-0.75%+3.32%+32.53%+97.21% 194B
Average -0.40%+3.06%+26.12%+48.61% 394.09B
Weighted average by Cap. +0.13%+3.83%+39.18%+71.44%

Financials

2025 2026
Net sales 3.18B 33.44M 29.76M 27.54M 25.09M 47.3M 48.16M 331M 130M 1.66B 125M 123M 5.29B 2.32B 24.45M 21.75M 20.13M 18.34M 34.57M 35.2M 242M 95.02M 1.21B 91.73M 89.78M 3.86B
Net income 67.21M 708K 630K 583K 531K 1M 1.02M 7M 2.75M 35.04M 2.66M 2.6M 112M -444M -4.68M -4.16M -3.85M -3.51M -6.61M -6.73M -46.28M -18.17M -231M -17.55M -17.17M -739M
Net Debt 936M 9.86M 8.78M 8.12M 7.4M 13.95M 14.2M 97.6M 38.33M 488M 37M 36.22M 1.56B 1.12B 11.8M 10.5M 9.72M 8.85M 16.69M 16.99M 117M 45.87M 584M 44.28M 43.34M 1.86B
Projected Income Statement - Annual - Mangalam Drugs & Organics Limited
Logo Mangalam Drugs & Organics Limited
Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemical products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed for research and development) is Bictegravir Na (IH).
Employees
319
Date Price Change Volume
16/10/26 ₹30.88 -2.37% 4,233
15/10/26 ₹31.63 -1.65% 3,607
14/10/26 ₹32.16 +1.16% 211
13/10/26 ₹31.79 +0.35% 270
12/10/26 ₹31.68 +0.57% 2,415
  1. Stock Market
  2. Stocks
  3. MANGALAM Stock